Pulse Biosciences unveils late-breaking first-in-human feasibility data for its nPulse Cardiac Catheter System at the 2026 AF Symposium, citing high 6- and 12-month atrial fibrillation ablation success and a favorable safety profile; an SEC filing specifies the feasibility study achieved a 96% one-year success rate.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.